Cost Analysis of Neratinib in an Extended Adjuvant Treatment Setting for Patients with Early-Stage, HR-Positive, HER2-Positive Breast Cancer

Web Exclusives —December 18, 2020

In the United States, neratinib (Nerlynx), an oral, irreversible tyrosine kinase inhibitor of multiple human epidermal growth factor receptors (HERs), is indicated for the extended adjuvant treatment of adult patients with HER2-positive early-stage breast cancer to follow adjuvant trastuzumab (Herceptin)-based therapy. Greater efficacy has been observed in patients with hormone receptor (HR)-positive breast cancer and who initiated neratinib within 1 year of completing trastuzumab. From a US third-party payer perspective, Thor-Henrik Brodtkorb, PhD, Senior Director, Health Economics, RTI Health Solutions, Ljungskile, Sweden, and colleagues investigated the cost-effectiveness of neratinib therapy in this patient population.

To compare the costs per treatment arm, a calculation was made based on drug acquisition, administration, and monitoring costs, in addition to treatment costs for health state–related medical resource uses and side effects.

The analyses found that neratinib treatment resulted in a cost gain of $56,367 when compared with placebo. Patients who did not achieve a pathologic complete response after neoadjuvant therapy resulted in an improved incremental cost-effectiveness ratio.

Based on these studies, neratinib is a cost-effective therapy for treating adult patients with HR-positive, HER2-positive early-stage breast cancer, who are less than 1 year from the completion of previous adjuvant trastuzumab-based therapy and in patients who did not achieve a pathologic complete response after neoadjuvant treatment.

Related Articles
Early Intervention Strategies for Management of Alpelisib-Induced Hyperglycemia
Web Exclusives
Preliminary recommendations made based on cases from the SOLAR-1 trial suggest that alpelisib-induced hyperglycemia can be managed with early detection, close monitoring, and prompt intervention.
Effect of Multiple Certified Educational Activities on Knowledge and Competence with CDK4/6 Inhibitors in HR-Positive Breast Cancer
Web Exclusives
Participation in certified educational activities resulted in significant improvements in knowledge, competence, and confidence regarding the use of CDK4/6 inhibitor therapies in the management of patients with advanced HR-positive breast cancer.
Randomized Phase 3 Trial of Endocrine Therapy plus Entinostat in Patients with HR-Positive Advanced Breast Cancer
Web Exclusives
The combination of exemestane and entinostat did not show survival benefit in patients with aromatase inhibitor–resistant, HR-positive, HER2-negative advanced breast cancer.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country